Aclarion, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
ACON$1.75+5.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net income (loss) | $(3,638,193) | $(3,637,180) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 107,729 | 90,864 |
| Share-based compensation | 84,257 | 156,131 |
| Amendment of warrants | 48,087 | – |
| Non-cash settlements | 58,272 | – |
| Loss on exchange of debt | – | 1,066,732 |
| Loss on extinguishment of debt | – | 111,928 |
| Amortization of deferred issuance costs | – | 491,405 |
| Change in fair value related to warrants and derivative | (11,766) | (323,041) |
| Change in assets and liabilities | ||
| Accounts receivable | (2,595) | (5,115) |
| Prepaids and other current assets | (232,111) | (405,657) |
| Accounts payable | (268,237) | (540,710) |
| Accrued and other liabilities | (521,837) | (267,325) |
| Note payable, net of discount | – | (31,129) |
| Net cash (used in) operations | (4,376,394) | (3,293,096) |
| Investing activities | ||
| Intangible assets – Patents | (121,810) | (157,523) |
| Fixed assets | (481) | – |
| Net cash (used in) investing activities | (122,290) | (157,523) |
| Financing activities | ||
| Public offering of common stock and warrants | 14,554,545 | 3,001,495 |
| Registered Direct offerings | 5,167,927 | – |
| Proceeds from equity line | – | 1,754,032 |
| Common stock cash issuance costs | (1,959,643) | (828,941) |
| Repayment of promissory notes | – | (300,973) |
| Bridge fund cash issuance costs | – | (23,375) |
| Exercise of Series C warrants | 336,441 | – |
| Redemption of Series B Preferred stock | (1,213,590) | – |
| Net cash provided by financing activities | 16,885,680 | 3,602,237 |
| Net increase (decrease) in cash and cash equivalents | 12,386,996 | 151,618 |
| Cash, cash equivalents and restricted cash, beginning of period | 463,661 | 1,031,069 |
| Cash, cash equivalents and restricted cash, end of period | $12,850,657 | $1,182,687 |
| Non-cash activities | ||
| Issuance of common shares in exchange for debt | $– | $1,519,779 |
| Issuance of bridge fund commitment shares | $– | $33,297 |
| Capitalization of Series B preferred stock dividends | $5,425 | $– |
| Capitalization of Series C preferred stock dividends | $1,258 | $– |
| Conversion of Series C preferred stock to common stock | $548,534 | $– |
| Cashless exercise of B warrants to common stock | $9,539,081 | $– |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.